Скачать или смотреть Phase II study of acalabrutinib, venetoclax, and obinutuzumab in CLL enriched for high-risk disease

Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the primary results of a multicenter, Phase II study (NCT03580928) of acalabrutinib, venetoclax, and obinutuzumab (AVO) in a population of previously untreated patients with chronic lymphocytic leukemia (CLL) enriched for high-risk disease with TP53 aberration. Dr Davids highlights that in the study, 42% of patients achieved a complete remission (CR) with undetectable measurable residual disease (MRD) at cycle 16, and at a median follow-up of 55 months, the progression-free survival (PFS) was around 70%. This study complements the larger Phase III AMPLIFY trial data (NCT03836261) in non-TP53 aberrant disease and suggests the potential synergy of combining different mechanisms in high-risk patients. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.